144 related articles for article (PubMed ID: 38617448)
1. Identification of an immune-related gene signature for predicting prognosis and immunotherapy efficacy in liver cancer
Li JT; Zhang HM; Wang W; Wei DQ
World J Gastroenterol; 2024 Mar; 30(11):1609-1620. PubMed ID: 38617448
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
3. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
4. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
6. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
7. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy.
Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y
Front Immunol; 2023; 14():1128390. PubMed ID: 36761753
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
10. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
13. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
[TBL] [Abstract][Full Text] [Related]
14. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
17. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
18. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
19. A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing.
Xiang X; Kang J; Jiang J; Zhang Y; Zhang Y; Li L; Peng X
Front Immunol; 2023; 14():1198391. PubMed ID: 37449209
[TBL] [Abstract][Full Text] [Related]
20. Malignant cell receptor-ligand subtypes guide the prediction of prognosis and personalized immunotherapy of liver cancer.
Wu J; Wu C; Cai X; Li P; Lin J; Wang F
Aging (Albany NY); 2024 Jan; 16(2):1712-1732. PubMed ID: 38244584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
